{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Component+B&page=17", "query": { "intervention": "Component B", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 399, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Component+B&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Component+B&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T20:17:35.274Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04825223", "title": "Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Meningococcal Immunisation", "Healthy Volunteers" ], "interventions": [ { "name": "Multicomponent Meningococcal B Vaccine", "type": "DRUG" }, { "name": "Meningococcal Group B Vaccine MenB", "type": "DRUG" }, { "name": "Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "50 Years", "sex": "ALL", "summary": "42 Days to 50 Years" }, "enrollment_count": 576, "start_date": "2021-03-29", "completion_date": "2022-07-22", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 8, "location_summary": "Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "El Dorado", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04825223" }, { "nct_id": "NCT05800405", "title": "Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-07-20", "completion_date": "2027-01-04", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800405" }, { "nct_id": "NCT02570542", "title": "Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B-cell Lymphoma (DLBCL)", "Refractory Diffuse Large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "carmustine, etoposide, cytarabine, melphalan", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 14, "location_summary": "Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02570542" }, { "nct_id": "NCT02975596", "title": "MenB Vaccine: Implementation Via Information, Empowerment and Accessibility", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Meningococcal Vaccine" ], "interventions": [ { "name": "Awareness", "type": "OTHER" }, { "name": "Education", "type": "OTHER" }, { "name": "Empowerment", "type": "OTHER" }, { "name": "Accessibility", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "16 Years to 99 Years" }, "enrollment_count": 1326, "start_date": "2016-12", "completion_date": "2019-10-08", "has_results": false, "last_update_posted_date": "2020-02-06", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 6, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02975596" }, { "nct_id": "NCT06702007", "title": "Electronic Harm Reduction Treatment for Alcohol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alcohol Use Disorder", "Harm Reduction", "Housing First (eg. Permanent Supportive Housing)" ], "interventions": [ { "name": "eHaRT-A", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 160, "start_date": "2025-01-20", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-07-08", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06702007" }, { "nct_id": "NCT04096040", "title": "Benefits of Microcor in Ambulatory Decompensated Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "μCor", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Zoll Medical Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 265, "start_date": "2019-11-01", "completion_date": "2023-10-30", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 67, "location_summary": "Sheffield, Alabama • El Cajon, California • Inglewood, California + 60 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "El Cajon", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04096040" }, { "nct_id": "NCT02164539", "title": "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "VI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2014-07-01", "completion_date": "2015-07-18", "has_results": true, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 14, "location_summary": "Newport Beach, California • San Diego, California • Upland, California + 11 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164539" }, { "nct_id": "NCT03103971", "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Adult Acute Lymphoblastic Leukemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements" ], "interventions": [ { "name": "Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2017-11-03", "completion_date": "2024-03-23", "has_results": false, "last_update_posted_date": "2024-04-10", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103971" }, { "nct_id": "NCT05585632", "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SARS-CoV-2", "Influenza", "RSV" ], "interventions": [ { "name": "mRNA-1010", "type": "BIOLOGICAL" }, { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.214", "type": "BIOLOGICAL" }, { "name": "mRNA-1045", "type": "BIOLOGICAL" }, { "name": "mRNA-1230", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 392, "start_date": "2022-10-14", "completion_date": "2024-02-28", "has_results": false, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 14, "location_summary": "DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585632" }, { "nct_id": "NCT02844478", "title": "Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress, Psychological", "Telomere Shortening", "Stress, Physiological" ], "interventions": [ { "name": "SBP English", "type": "BEHAVIORAL" }, { "name": "SBP SPANISH", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-09", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-24T20:17:35.274Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02844478" } ] }